ArticleMolecular biology reports2025
Proteome cargo and functional heterogeneity of extracellular vesicles derived from stem cells and differentiated cells of human trabecular meshwork.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNA profiling of filtering and non-filtering regions of human trabecular meshwork: changes with ageing and in glaucoma.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGlaucoma, an optic neuropathy, is the second leading cause of irreversible blindness worldwide. Wound healing efficiency and anti-oxidant potential of the small extracellular vesicles (sEV) isolated from the adult tissue-resident stem cells of the trabecular meshwork (TMSC) compared to trabecular meshwork (TM) cells have been demonstrated. This study aimed to compare the protein profile of extracellular vesicles derived from TMSCs and TM cells for a better understanding of their potential as a cell-free therapeutic agent for primary open angle glaucoma (POAG). METHODS AND
resultsProteins were isolated from TM and TMSC sEV samples (n = 3 each) and proteomic profiling was carried out by mass spectrometry. Mass spectrometry analysis identified 2802 proteins in TMSC sEV and 2848 in TM sEV. Differential expression analysis identified distinct protein profiles between TMSC and TM sEV. Notably, sEV from TMSCs were enriched with proteins associated with wound healing, cell proliferation, migration, anti-oxidant, and anti-apoptotic activities, consistent with the findings in other mesenchymal stem cells. Pathway analysis highlighted the enrichment of proteins associated with PI3K-AKT and MAPK signaling pathways. Further validation by western blotting confirmed that TMSC sEV effectively modulated these pathways in TM cells, which are essential for cell proliferation and survival under oxidative stress.
conclusionTo our knowledge, this is the first comprehensive protein profiling of TMSC-derived sEV, demonstrating the presence of functional proteins and their capacity to regulate the MAPK and PI3K-AKT signaling pathways in the recipient TM cells. This highlights the potential of TMSC sEV in advancing cell-free therapeutic strategies for POAG in future.
Indexed as
Identifiers
40481930What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.